Literature DB >> 2981527

Platelet activation.

M B Zucker, V T Nachmias.   

Abstract

Platelets are discoidal cytoplasmic particles that respond to a variety of stimuli by developing filopodia and rounding up (shape change), developing the ability to bind fibrinogen from the medium, and, with strong stimuli such as thrombin and PAF-acether, secreting the contents of several types of granules. Arachidonic acid is cleaved from phospholipids by phospholipase A2 and converted by the platelets to endoperoxides, and then to thromboxane A2. The bound dimeric fibrinogen molecules probably cause aggregation by forming bridges between platelets. Aggregation is reinforced by secreted fibrinogen and thrombospondin, which binds the platelets, and by thromboxane A2 and endoperoxides, as well as secreted ADP, which cause additional receptor-mediated activation. The responses to these stimuli are initiated when the agonists bind to specific receptors on the plasma membrane. Subsequent steps resemble those in other types of responsive cells: breakdown of phosphatidylinositol bisphosphate into diacylglycerol, a stimulator of protein kinase C, and inositol-1,4,5-trisphosphate, recently shown to be a potent calcium ionophore. The response of shape change results from increased cytoplasmic Ca2+ which permits phosphorylation of one of the light chains of myosin by a calcium-calmodulin-dependent kinase, with resulting enhanced actin-myosin interaction. Secretion is associated with phosphorylation of a 40,000 to 47,000 dalton protein by the diacylglycerol-activated protein kinase C. These recent findings have increased our understanding of the mechanisms of platelet activation, but much remains to be learned. How do agonist-receptor complexes influence PIP2 breakdown? Is this indeed the first step in activation? What mediates adhesion of platelets to the injured blood vessel wall? Does transduction of this stimulus occur by the same mechanism as transduction of commonly used soluble stimuli? What is the role of the phosphorylated 40-47 K protein in secretion? What change in GP IIb-IIIa promotes their ability to bind fibrinogen? What is the role of calcium-activated protease? Of the phosphorylation of actin-binding protein? Progress is being made rapidly, and these questions may be answered within a few years.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981527     DOI: 10.1161/01.atv.5.1.2

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  41 in total

1.  Inhibition of human platelet adenylate cyclase by collagen fibres. Effect of collagen is additive with that of adrenaline, but interactive with that of thrombin.

Authors:  R W Farndale; A B Winkler; B R Martin; M J Barnes
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

2.  Temperature effects on the activity, shape, and storage of platelets from 13-lined ground squirrels.

Authors:  Scott Cooper; Sarah Lloyd; Anthony Koch; Xingxing Lin; Katie Dobbs; Thomas Theisen; Matt Zuberbuehler; Kaley Bernhardt; Michael Gyorfi; Tanner Tenpas; Skyler Hying; Sarah Mortimer; Christine Lamont; Marcus Lehmann; Keith Neeves
Journal:  J Comp Physiol B       Date:  2017-03-23       Impact factor: 2.200

3.  Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability.

Authors:  Hidemi Hattori; Masayuki Ishihara
Journal:  Exp Ther Med       Date:  2017-01-13       Impact factor: 2.447

4.  Biochemical mechanisms in 5-hydroxytryptamine-induced human platelet aggregation.

Authors:  F de Clerck; B Xhonneux; R van de Wiele
Journal:  Agents Actions       Date:  1985-12

5.  Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.

Authors:  K M Tang; E K Jang; R J Haslam
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

Review 6.  The use of CD47-modified biomaterials to mitigate the immune response.

Authors:  Jillian E Tengood; Robert J Levy; Stanley J Stachelek
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

7.  Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions.

Authors:  H Kankaanranta; E Moilanen; H Vapaatalo
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

Review 8.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

Review 9.  Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family?

Authors:  Harold J Ting; Fadi T Khasawneh
Journal:  J Biomed Sci       Date:  2010-04-06       Impact factor: 8.410

10.  Evidence for regulation of human platelet adenylate cyclase by phosphorylation. Inhibition by ATP and guanosine 5'-[beta-thio]diphosphate occur by distinct mechanisms.

Authors:  I A Wadman; R W Farndale; B R Martin
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.